Neumora Therapeutics (NMRA) Projected to Post Quarterly Earnings on Tuesday

Neumora Therapeutics (NASDAQ:NMRA) will likely be issuing its Q3 2025 results before the market opens on Tuesday, November 11th. Analysts expect the company to announce earnings of ($0.34) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Tuesday, November 11, 2025 at 8:00 AM ET.

Neumora Therapeutics (NASDAQ:NMRA) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.05. On average, analysts expect Neumora Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Neumora Therapeutics Stock Down 4.3%

Shares of NASDAQ NMRA traded down $0.13 during mid-day trading on Tuesday, reaching $2.88. 904,195 shares of the company were exchanged, compared to its average volume of 1,901,125. The stock has a market cap of $466.56 million, a price-to-earnings ratio of -1.83 and a beta of 2.92. The firm has a 50-day moving average of $1.90 and a 200 day moving average of $1.38. Neumora Therapeutics has a 1 year low of $0.61 and a 1 year high of $14.09. The company has a quick ratio of 10.54, a current ratio of 10.54 and a debt-to-equity ratio of 0.11.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. Needham & Company LLC increased their target price on shares of Neumora Therapeutics from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Tuesday, October 28th. Mizuho raised their target price on shares of Neumora Therapeutics from $4.00 to $5.00 and gave the stock an “outperform” rating in a report on Wednesday, July 16th. Guggenheim upgraded shares of Neumora Therapeutics from a “neutral” rating to a “buy” rating and set a $14.00 price target on the stock in a research report on Monday, October 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Neumora Therapeutics in a research report on Wednesday, October 8th. Finally, JPMorgan Chase & Co. lowered shares of Neumora Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Tuesday, September 16th. Four equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $8.38.

Insider Buying and Selling

In other news, Director Kristina Burow bought 1,915,700 shares of the firm’s stock in a transaction on Monday, October 27th. The shares were bought at an average cost of $2.61 per share, for a total transaction of $4,999,977.00. Following the acquisition, the director directly owned 6,046,907 shares of the company’s stock, valued at $15,782,427.27. This trade represents a 46.37% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Arch Venture Partners Xii, Llc bought 1,915,700 shares of the firm’s stock in a transaction on Monday, October 27th. The stock was purchased at an average price of $2.61 per share, for a total transaction of $4,999,977.00. Following the completion of the acquisition, the insider directly owned 6,046,907 shares in the company, valued at $15,782,427.27. The trade was a 46.37% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 26.80% of the company’s stock.

Hedge Funds Weigh In On Neumora Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of NMRA. Canada Pension Plan Investment Board acquired a new position in shares of Neumora Therapeutics in the 2nd quarter worth approximately $41,000. Russell Investments Group Ltd. increased its position in shares of Neumora Therapeutics by 2,898.1% in the 2nd quarter. Russell Investments Group Ltd. now owns 73,812 shares of the company’s stock valued at $56,000 after purchasing an additional 71,350 shares during the last quarter. Bridgeway Capital Management LLC purchased a new stake in shares of Neumora Therapeutics in the 2nd quarter valued at approximately $92,000. Invesco Ltd. grew its position in shares of Neumora Therapeutics by 6.8% in the 2nd quarter. Invesco Ltd. now owns 132,038 shares of the company’s stock valued at $97,000 after buying an additional 8,383 shares during the last quarter. Finally, Sei Investments Co. purchased a new position in shares of Neumora Therapeutics in the 2nd quarter valued at $157,000. 47.65% of the stock is currently owned by institutional investors and hedge funds.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.